Potential utility of the Genedrive point-of-care test for HCV RNA detection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Quality Assurance for Hepatitis C Virus Point-of-Care Diagnostics in Sub-Saharan Africa.Diagnostics (Basel, Switzerland) · 2023
   Review
2. Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification-Lateral Flow Dipstick.Frontiers in cellular and infection microbiology · 2022
   Article
3. Diagnostic Performance and Usability of the GenedriveDiagnostics (Basel, Switzerland) · 2021
   Article
4. Offline Next Generation Metagenomics Sequence Analysis Using MinION Detection Software (MINDS).Genes · 2019
   Article

Corrections and comments

• Comment on
  Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.2018
• Comment on
  What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? '2018

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as